×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
NASDAQ:ITRM

Iterum Therapeutics Stock Forecast, Price & News

$0.22
+0.03 (+15.71%)
(As of 06/29/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.19
$0.28
50-Day Range
$0.19
$0.30
52-Week Range
$0.18
$2.48
Volume
7.10 million shs
Average Volume
1.31 million shs
Market Capitalization
$40.52 million
P/E Ratio
11.06
Dividend Yield
N/A
Price Target
$0.70
30 days | 90 days | 365 days | Advanced Chart

Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITRM Stock Forecast (MarketRank)

Overall MarketRank

1.77 out of 5 stars

Medical Sector

843rd out of 1,433 stocks

Pharmaceutical Preparations Industry

417th out of 685 stocks

Analyst Opinion: 2.8Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
Iterum Therapeutics logo

About Iterum Therapeutics (NASDAQ:ITRM)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

ITRM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITRM
Fax
N/A
Employees
13
Year Founded
N/A

Company Calendar

Last Earnings
5/13/2022
Today
6/29/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$0.70
High Stock Price Forecast
$0.70
Low Stock Price Forecast
$0.69
Forecasted Upside/Downside
+214.5%
Consensus Rating
Hold
Rating Score (0-4)
1.66666666666667
Research Coverage
3 Analysts

Profitability

Net Income
$-91.56 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$40 thousand
Book Value
$0.27 per share

Miscellaneous

Free Float
174,185,000
Market Cap
$40.52 million
Optionable
Not Optionable
Beta
1.21














Iterum Therapeutics Frequently Asked Questions

Should I buy or sell Iterum Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Iterum Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ITRM, but not buy additional shares or sell existing shares.
View analyst ratings for Iterum Therapeutics
or view top-rated stocks.

What is Iterum Therapeutics' stock price forecast for 2022?

3 brokers have issued 1-year target prices for Iterum Therapeutics' stock. Their ITRM stock forecasts range from $0.69 to $0.70. On average, they predict Iterum Therapeutics' stock price to reach $0.70 in the next year. This suggests a possible upside of 213.2% from the stock's current price.
View analysts' price targets for Iterum Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Iterum Therapeutics' stock price performed in 2022?

Iterum Therapeutics' stock was trading at $0.3920 at the beginning of 2022. Since then, ITRM shares have decreased by 43.4% and is now trading at $0.2219.
View the best growth stocks for 2022 here
.

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Iterum Therapeutics
.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) issued its quarterly earnings data on Friday, May, 13th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03.
View Iterum Therapeutics' earnings history
.

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the following people:
  • Mr. Corey N. Fishman, Pres, CEO & Director (Age 57, Pay $939.26k)
  • Ms. Judith M. Matthews, Chief Financial Officer (Age 52, Pay $533.85k)
  • Dr. Michael W. Dunne M.D., Strategic Advisor & Director (Age 62, Pay $377.8k)
  • Dr. Sailaja Puttagunta M.D., Chief Medical Officer (Age 53, Pay $125.79k)
  • Mr. Tom Loughman Ph.D., Sr. VP of Technical Operations
  • Ms. Louise Barrett, Sr. VP of Legal Affairs & Sec.
  • Dr. Steven I. Aronin M.D., Sr. VP & Head of Clinical Devel.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), (NINE) and Ocugen (OCGN).

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

Who are Iterum Therapeutics' major shareholders?

Iterum Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.15%). Company insiders that own Iterum Therapeutics stock include Alexander J Denner, Corey N Fishman, Judith M Matthews, Michael W Dunne and Sofinnova Venture Partners Ix,.
View institutional ownership trends for Iterum Therapeutics
.

Which major investors are selling Iterum Therapeutics stock?

ITRM stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have sold Iterum Therapeutics company stock in the last two years include Alexander J Denner, Corey N Fishman, Judith M Matthews, and Michael W Dunne.
View insider buying and selling activity for Iterum Therapeutics
or view top insider-selling stocks.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $0.22.

How much money does Iterum Therapeutics make?

Iterum Therapeutics (NASDAQ:ITRM) has a market capitalization of $40.69 million and generates $40 thousand in revenue each year. The company earns $-91.56 million in net income (profit) each year or $0.019990 on an earnings per share basis.

How many employees does Iterum Therapeutics have?

Iterum Therapeutics employs 13 workers across the globe.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The official website for Iterum Therapeutics is www.iterumtx.com. The company can be reached via phone at (531) 903-8920 or via email at [email protected].

This page (NASDAQ:ITRM) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.